On May 24, the Human Resources and Social Security Bureau and the Health and Family Planning Committee of Shenzhen jointly issued a document to add Chidamide(trade name: Epidaza?), the original anti-tumor drug to the Shenzhen local supplementary medical drug list. It is applicable to peripheral T-cell lymphoma (PTCL), which has relapsed or is refractory to at least one systemic chemotherapy, and was officially implemented on June 1, 2016.

Chidamide (trade name: Epidaza?) is a new generation of epigenetic regulatory drugs originally created by Shenzhen microchip biotech co., ltd. Its main indication is for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) who have received at least one systemic chemotherapy in the past. Anti-tumor class 1.1 chemical new drug for oral subtype selective histone deacetylase inhibitor is the first approved drug for treating relapsed or refractory PTCL in China, which is also the first chemical new drug independently developed by China for simultaneous global development. The drug was approved for listing by CFDA on December 23, 2014. Widely used in clinic. On April 30, 2016, the " Chidamide consensus of Chinese experts on the treatment of peripheral T-cell lymphoma ( 2016 edition )" was officially released, which will push the clinical treatment of PTCL in China to a new stage.

In order to reduce the economic pressure on patients caused by serious and extraordinary diseases and prevent poverty caused by illness, Human Resources and Social Security Bureau of Shenzhen took the lead in organizing a group of experts ( clinical, pharmaceutical and pharmacoeconomic experts ) to conduct in-depth investigation and discussion on the clinical efficacy, safety, and patient benefits of Chidamide ( trade name: Epidaza? ). After discussion by the expert group, it was confirmed that Chidamide ( trade name: Epidaza? ) would be added to the local supplementary medical insurance list of Shenzhen so that patients with T-cell lymphoma in Shenzhen could enjoy this medical insurance treatment, obtain new drug treatment opportunities in time and benefit more.

In order to help patients benefit from new drugs, Chidamide ( trade name: Epidaza? ) has implemented the follow-up free medication program since it was launched on the market ( look www.aipusha.com for details ). So far, hundreds of patients have received assistance. Following the implementation of local medical insurance in Shenzhen, the follow-up free medication program will continue to be effective for eligible patients in Shenzhen.